Industry Overview

Grave’s disease diagnosis and treatment market was valued at $895.2 million in 2025 and is projected to reach $1,417.3 million by 2035, growing at a CAGR of 4.8% during the forecast Period (2026-2035). The market is growing, driven by rising autoimmune disorder cases, better awareness, and tech advances in diagnostics (like TSH tests, ultrasound, antibody assays) and treatments (anti-thyroid drugs, radioactive iodine, surgery), with North America leading and Asia-Pacific growing fast; however, high drug costs are a restraint. Its key factors include increasing incidence, early screening, personalized medicine, telehealth expansion, and the need for novel therapies for resistant cases, particularly for Graves' Orbitopathy (TED).

Market Dynamics 

Rising Prevalence of Autoimmune Thyroid Disorders and Increased Disease Awareness

A primary driver propelling the global grave’s disease diagnosis and treatment market is the growing incidence of autoimmune thyroid disorders, especially Graves’ disease, which is a leading cause of hyperthyroidism worldwide. Factors such as genetic susceptibility, environmental triggers, and lifestyle influences have contributed to a steady rise in diagnosed cases. As awareness about the condition increases among both patients and healthcare professionals, more individuals seek timely medical evaluation, leading to higher demand for diagnostic testing and treatment interventions. Improved education initiatives and public health campaigns highlighting symptoms such as weight loss, palpitations, and eye involvement are encouraging early diagnosis and care, which expands the overall market footprint.

Advancements in Diagnostic Technologies and Personalized Treatment Approaches

Technological progress in diagnostic tools and therapeutic options is another critical market driver. The development of highly sensitive blood tests for thyroid-stimulating immunoglobulins, advanced imaging modalities like high-resolution ultrasound, and improved laboratory assays enables earlier and more accurate disease detection. These innovations not only facilitate prompt diagnosis but also support tailored treatment planning, resulting in better disease management and patient outcomes. On the treatment side, ongoing research has led to novel pharmacological therapies, refined surgical techniques, and exploration of targeted treatments that address specific aspects of the disease pathology. As a result, clinicians can design more personalized and effective care pathways, increasing the adoption of advanced diagnostics and treatments across global healthcare systems.

Expansion of Healthcare Infrastructure and Increased Healthcare Spending

Expanding healthcare infrastructure, particularly in emerging economies, and rising healthcare expenditure are driving market growth by improving access to diagnostic and therapeutic services for Graves’ disease. Investments in endocrinology services, diagnostic laboratories, and specialized care centers have enhanced the availability of both basic screening and advanced treatment options. Additionally, telemedicine integration and digital health platforms are extending reach into previously underserved populations, allowing for remote monitoring, consultations, and follow?ups. Coupled with broader insurance coverage and government support for chronic disease management, these systemic improvements are enabling more patients to undergo diagnosis and pursue long?term treatment, thereby enlarging the overall market.

Market Segmentation

• Based on the diagnosis, the market is segmented into ultrasound, imaging test, RIA, and blood sample.
• Based on the treatment, the market is segmented into anti-thyroid medication, radioactive iodine therapy, and surgery.

Blood Sample Segment to Grow at a Considerable Market Share

In the global graves’ disease diagnosis and treatment market, blood sample testing under the diagnosis segment is poised to lead the market over the forecast period. blood tests are the primary diagnostic tool for graves’ disease, as they allow clinicians to measure thyroid-stimulating hormone (TSH), free thyroxine (T4), and triiodothyronine (T3) levels accurately, providing rapid and reliable confirmation of hyperthyroidism.

Additionally, the measurement of thyroid-stimulating immunoglobulins (TSI) has become a critical marker for identifying Graves’ disease specifically, further strengthening the dominance of blood-based diagnostics. Compared to imaging tests, ultrasounds, and radioactive iodine uptake (RAIU), blood samples are minimally invasive, cost-effective, and widely available across healthcare settings, including hospitals, clinics, and diagnostic laboratories. This accessibility, coupled with the rising prevalence of autoimmune thyroid disorders globally, ensures sustained demand for blood-based diagnostic tests. Furthermore, advancements in laboratory technologies and automation have improved the accuracy and turnaround time of these tests, making them indispensable in both initial diagnosis and ongoing disease monitoring. Blood sample testing also plays a pivotal role in treatment planning, helping physicians determine the appropriate course of antithyroid medications, RAI therapy, or surgical intervention, which in turn supports better patient outcomes. Collectively, these factors make blood sample diagnostics the largest and most influential segment driving growth in the global Graves’ disease diagnosis and treatment market.

Antithyroid Medication: A Key Segment in Market Growth

In the global graves’ disease diagnosis and treatment market, antithyroid medication emerges as the key segment driving significant market growth. Antithyroid drugs, including methimazole and propylthiouracil, are widely preferred due to their non-invasive nature, effectiveness in controlling hyperthyroidism, and suitability for long-term management, especially in patients who are not ideal candidates for surgery or radioactive iodine therapy. The increasing prevalence of Graves’ disease, coupled with a growing awareness among patients and healthcare providers about early diagnosis and treatment, has amplified the demand for antithyroid medications.

Additionally, these drugs are critical in managing disease recurrence and mitigating complications such as thyroid storm, further reinforcing their central role in treatment protocols. The segment’s growth is also supported by advancements in drug formulations that improve patient compliance, reduce adverse effects, and enable personalized dosing. Geographically, regions with robust healthcare infrastructure, rising geriatric populations, and higher diagnostic capabilities, such as North America and Europe, show increased adoption of antithyroid therapy. Its ongoing research, favorable reimbursement policies, and rising patient preference for non-surgical interventions, the antithyroid medication segment is poised to maintain its leading position and significantly contribute to the overall expansion of the global Graves’ disease treatment market over the forecast period.

In the global Grave’s Disease Diagnosis and Treatment market, e-glass emerges as the key segment by fibre type, driving significant growth over the forecast period.

Regional Outlook

the global grave’s disease diagnosis and treatment market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global graves’ disease diagnosis and treatment market, holding a major share over the forecast period. This leadership is primarily driven by the country’s advanced healthcare infrastructure, high awareness of thyroid disorders, and widespread availability of diagnostic and treatment facilities. In the US, early detection and precise management of Graves’ disease are prioritized, with routine blood tests, imaging, and advanced radioactive iodine uptake procedures being readily accessible.

Moreover, the presence of well-established pharmaceutical companies producing antithyroid medications and advanced RAI therapies supports the country’s strong treatment landscape. Favorable reimbursement policies, a high per capita healthcare expenditure, and the adoption of technologically advanced diagnostic equipment further reinforce the market’s growth in the region. Additionally, the rising prevalence of autoimmune disorders, including Graves’ disease, coupled with an aging population, has increased the demand for timely diagnosis and effective treatment. Research initiatives, clinical trials, and the growing emphasis on personalized medicine also contribute to enhancing the quality and efficacy of care in the US, setting a benchmark for other regions. Collectively, these factors ensure that the United States remains the leading country in the global Graves’ disease diagnosis and treatment market, both in terms of market size and adoption of innovative healthcare solutions.

Market Players Outlook

The major companies operating in the global grave’s disease diagnosis and treatment market include Abbott Laboratories, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co., Inc. (Merck KGaA), Novartis AG, Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In May?2025, Viridian Therapeutics received FDA Breakthrough Therapy Designation for veligrotug (VRDN-001) for treating thyroid eye disease, accelerating regulatory review timelines and validating the IGF-1R antagonist approach for autoimmune complications of Graves' disease. This designation positions veligrotug for potential commercial launch in 2026 following BLA submission in late 2025.
• In May?2025, Amgen’s TEPEZZA (teprotumumab) approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for moderate?to?severe thyroid eye disease, marking an important regulatory milestone for specific TED treatment.
• In January?2025, Sanofi initiated a Phase?II clinical trial for a novel biologic targeting thyroid?stimulating immunoglobulins (TSI) in Graves’ disease patients, aiming to directly neutralize the autoimmune drivers of the condition

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global grave’s disease diagnosis and treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.